Secondary Pharmaceutical Packaging

Primary Pharmaceutical Packaging 

Blister lines for solid dosage forms
Tablets, sugar-coated tablets, capsules, oblongs, syringes, etc.
Films/foils: PVC, PVC/ PVdC, PVC/PE/PVdC, PVC/ACLAR/PVC, COC-Laminates, PP, PET, Tyvec or alu/alu (with/without childproof seals)
...

On the basis of GMP-compliant processes – certified by the FDA and Swissmedic and in accordance with PMDA standards (Japan) – our packaging operations satisfy the highest standards of quality. 

The packaging process - implemented by allpack group ag - with continuous serialization and...

When medicines are developed for rare diseases, every dose can make a difference. Small patient populations and changing demand require a packaging partner that understands the importance of flexibility.

This is where allpack group ag comes in. As a specialist in pharmaceutical packaging for orphan drugs, niche products and small-volume medicines, we offer tailored solutions with no minimum order quantities (MOQs). From blister and bottle packaging to serialization and aggregation, our services adapt to the individual needs of each product.

With modern facilities, GMP-compliant processes, sustainable packaging materials, and extensive international experience, allpack group ag combines quality, reliability and personal service, even when volumes are small and requirements are complex.

Because for us, it is never just a small batch. It is medicine intended for someone who needs it.

allpack – a leading service provider for pharmaceutical packaging

We are a GMP-compliant pharmaceutical contract packaging organisation (CPO) that has the passion and drive to create and produce well suitable and cost-efficient packaging solutions for our customers. Join us on a journey of discovery in our world of pharmaceutical contract packaging. All you need is allpack.

Our company fact sheet provides an overview of important information about our company. It is a compact and concise summary of our business.

Two years ago was the first day after the "point of no return" for prescription Rx and Gx medicines. The Falsified Medicines Directive (FMD) had been fully rolled out and serialisation had become mandatory. For most CPOs, CMOs and packaging departments of MAHs, the time prior to launch was relentless. Company systems, structures and culture had to integrate parallel computing as a new integral part of the physical packaging process. Early industry reports said there would be almost no long-term burden. Yes, that is true for big brands. But small brands and batch sizes struggle with the daily routine of additional serialisation sub-processes with aggregation as the icing on the cake. The lucky ones got an early start, like we did in 2014. When did your experience and learning curve start? Let's talk about it!